Aura Biosciences, Inc.

NASDAQ:AURA

Biotechnology

Healthcare
$7.14 -1.43%

-$0.09 today

Market cap
$743.09M
Beta
0.39
P/E (TTM)
-3.7
EPS (TTM)
-$1.67
52W Low $4.73High $9.54

Volume 0.69M

Average 0.52M

AURA Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Aura Biosciences, Inc.NASDAQ: AURA

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables outflow grows to $0

Q1 FY2026 accounts receivables was $0, compared with $0 a year earlier. Trailing-twelve-month accounts receivables was $0.

Context

  • Accounts receivables increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Accounts Receivables vs competitors

How AURA compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
AURA Competitors
Accounts Receivables for AURA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$19.05M USD-355.9%+58.8%250.2%
BCYCBicycle Therapeutics plcLTM Mar 2026$3.41M USD-86.4%—5.4%
AKTSAktis Oncology, Inc.FY2025$1.03M USD+220.1%—15.9%
WHWKWhitehawk Therapeutics IncLTM Dec 2025$1M USD+141.0%-18.7%14.0%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$968.41K USD——290.7%
OCSOculis Holding AGLTM Mar 2026CHF 272.05K CHF-142.6%—54.0%
MGNXMacroGenics, Inc.LTM Mar 2026$117K USD+103.5%-41.7%0.1%
AURAAura Biosciences, Inc.LTM Mar 2026$0 USD———
IMNMImmunome, Inc.LTM Sep 2026$0 USD———
OCGNOcugen, Inc.LTM Mar 2026$0 USD——0.0%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$0 USD———
Peer median (excluding AURA) —+8.6%-18.7%15.0%

Competitors are the stored peer set for AURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(35.25M)(58.76M)(76.41M)(86.92M)(106.19M)
Depreciation & Amortization831K1.18M1.3M1.22M1.13M
Deferred Income Tax14K0000
Stock-Based Compensation2.31M6.41M8.77M11.72M14.32M
Change in Working Capital(315K)(3.1M)4.44M(2.64M)5.97M
Accounts Receivables00000
Inventory00000
Accounts Payables1.05M340K(1.04M)482K(846K)
Other Working Capital(1.37M)(3.44M)5.48M(3.12M)6.82M
Other Non-Cash Items4K(325K)(1.95M)(3.19M)32K
Operating Cash Flow(32.41M)(54.6M)(63.85M)(79.81M)(84.74M)
Capital Expenditures(2.13M)(1.09M)(709K)(1.25M)(447K)
Acquisitions (Net)066.78K000
Purchases of Investments0(119.78M)(233.65M)(59.11M)(83.96M)
Sales of Investments053.01M120.4M129.18M120M
Other Investing Activities0(66.78K)000
Investing Cash Flow(2.13M)(67.87M)(113.96M)68.82M35.6M
Debt Repayment00000
Common Stock Issued78.7M8.55M3.17M1.6M77.16M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities334K430K1.5M00
Financing Cash Flow166.26M95.63M97.29M1.6M77.16M
Effect of Forex Changes0000(186K)
Net Change in Cash131.72M(26.84M)(80.52M)(9.39M)27.82M
Free Cash Flow(34.54M)(55.7M)(64.56M)(81.06M)(85.19M)

Aura Biosciences, Inc.

NASDAQ:AURA

Intrinsic Alpha fair value

Locked

Current Price

$7.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.